INNOVATION

REDEFINE WHAT IS POSSIBLE^®

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company is developing innovative therapies for neuropsychiatric disorders. The Company’s first indication is trichotillomania, a highly prevalent disorder for which there is no approved therapy. Alterations in glutamate signaling within brain regions implicated in urge control and executive function have been proposed to contribute to the underlying pathology of trichotillomania, as well as other obsessive-compulsive and addictive disorders, and other CNS conditions.